Leukemia Research
Volume 27, Issue 3 , Pages 221-229 , March 2003

A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q− syndrome from refractory anemia in primary myelodysplastic syndrome

  • Jaroslav Čermák

      Affiliations

    • Institute of Hematology and Blood Transfusion, U nemocnice 1, 128 20 Prague 2, Czech Republic
    • Corresponding Author InformationCorresponding author. Tel.: +420-2-2496-2839; fax: +420-2-2496-2857.
    • ,
  • Kyra Michalová

      Affiliations

    • Institute of Hematology and Blood Transfusion, U nemocnice 1, 128 20 Prague 2, Czech Republic
    • ,
  • Jana Březinová

      Affiliations

    • Institute of Hematology and Blood Transfusion, U nemocnice 1, 128 20 Prague 2, Czech Republic
    • ,
  • Zuzana Zemanová

      Affiliations

    • Third Department of Internal Medicine, Faculty Hospital, Prague 2, Czech Republic

Received 26 February 2002 ,Accepted 30 May 2002.

References 

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al.  Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982;51:189
  2. Vallespi T, Torrabadella M, Julia A, Irriguible D, Jaen A, Acebedo G, et al.  Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br. J. Haematol. 1985;61:83
  3. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 1985;59:425
  4. Goasguen JE, Garand R, Bizet M, Bremond JL, Gardais J, Callat MP, et al.  Prognostic factors of myelodysplastic syndromes—a simplified 3-D scoring system. Leuk. Res. 1990;14:255
  5. Jacobs RH, Cornbleet MA, Vardman JW, Larson RA, Le Beau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 1986;67:1765
  6. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, et al.  Cytogenetic analysis has a strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7:1315
  7. Nowell PC, Besa EC. Prognostic significance of single chromosome abnormalities in preleukemic states. Cancer Genet. Cytogenet. 1989;42:1
  8. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin. Hematol. 1996;33:127
  9. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br. J. Haematol. 1995;91:612
  10. Maschek H, Georgii A, Kaloutsi V, Werner M, Bandecar K, Kressel MG, et al.  Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur. J. Haematol. 1992;48:208
  11. Park DJ, Koeffler HP. Therapy-related myelodysplastic syndromes. Semin. Hematol. 1996;33:256
  12. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadela M, Garcia S, et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395
  13. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52
  14. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079
  15. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vradiman J, et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Adviosory Committee Meeting—Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999;17:3835
  16. Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin. Hematol. 1996;33:95
  17. Mittelman F, editor. ICSN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger, 1995.
  18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958;53:457
  19. Cox DR. Regression models and life-tables. J. R. Stat. Soc. 1972;34:187
  20. Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 1992;6:607
  21. Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, et al.  Refractory cytopenia with multilineage dysplasia: further characterization of unclassifiable myelodysplastic syndrome. Leukemia. 1996;10:20
  22. Kerkhofs H, Hermans J, Haak HL, Leeksma CHW. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol. 1987;65:73
  23. Foucar K, Langdon M, Armitage JO, Olson DB, Carroll TJ. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer. 1985;56:553
  24. Tricot G, Vlietinck R, Boogaerts MA, Hendrickx B, De Wolf-Peters C, Van den Berghe H, et al.  Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br. J. Haematol. 1985;60:19
  25. Greenberg P. Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin. Hematol. 1996;33:163
  26. Jelı́nek J, Šiškova M, Čermák J, Michalová K, Neuwirtová R. Leukemic growth of CFU-GM is an independent poor risk factor for survival and evolution of acute myeloid leukemia in MDS. Leuk. Res. 1999;23(Suppl. 1):S66
  27. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res. 2000;24:983
  28. Nösslinger T, Reisner R, Koller E, Grüner H, Tüchler H, Nowotny H, et al.  Myelodysplastic syndromes, from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 2001;98:2935
  29. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia. 2000;14:2
  30. Van Den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature. 1974;251:437
  31. Sokal G, Michaux JL, Van Den Berghe H, Cordier A, Rodhain J, Ferrant A, et al.  A new hematologic syndrome with a distinct karyotype: the 5q− chromosome. Blood. 1975;46:519
  32. Matthews P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC, et al.  The 5q− syndrome: a single institution study of 43 consecutive patients. Blood. 1993;81:1040
  33. Lewis S, Oscier D, Boultwood J, Ross F, Fitchett M, Rack K, et al.  Hematological features of patients with myelodysplastic syndrome associated with a chromosome 5q deletion. Am. J. Hematol. 1995;49:194
  34. Dewald GW, Davis MP, Pierre RV, O’Fallon JR, Hoagland HC. Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5. Blood. 1985;66:189
  35. Boultwood J, Lewis S, Wainscoat JS. The 5q− syndrome. Blood. 1994;84:3253
  36. Kearney L, Haas OA, Neat M, Harbott J, Boultwood J, Wainscoat JS, et al.  Whole chromosome painting and FISH with subtelomeric probes reveals cryptic chromosome rearrangements in del(5q) leukaemias: a UK Cancer Cytogenetic Group study. Cytogenet. Cell Genet. 1999;85:74
  37. Nagarajan L, Zhao L, Lu X, Warrington JA, Wasmuth JJ, Siciliano M, et al.  5q− chromosome. Evidence for complex interstitial breaks in a case of refractory anemia with excess blasts. Cancer Genet. Cytogenet. 1994;74:8
  38. Březinová J, Zemanová Z, Čermák J, Michalová K. Fluorescence in situ hybridization confirmation of 5q deletions in patients with hematological malignancies. Cancer Genet. Cytogenet. 2000;117:45
  39. Le Beau MM, Espinosa R, Neuman WL, Stock W, Roulston D, Larson RA, et al.  Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. U.S.A. 1993;90:5484

PII: S0145-2126(02)00096-6

Leukemia Research
Volume 27, Issue 3 , Pages 221-229 , March 2003

Article Tools

* Image Usage & Resolution